16/02/23 - Ipilimumab SMC2094 added.
16/02/23 - Nivolumab SMC1187/16, 2458 and 2503 added.
16/02/23 - Pembrolizumab powder for concentrate for solution for infusion SMC1296/18 added.
16/02/23 - Pembrolizumab SMC1296/18, SMC2460, SMC2474, SMC2479 and SMC2501 added for concentrate for solution for infusion 25mg/mL.
MHRA alert: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).
MHRA advice: Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) (June 2021) (www.gov.uk).
NICE Guidance: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019) (www.nice.org.uk).
Concentrate solution for infusion 840mg/14mL (hospital use only)
Solution for infusion 350mg (specialist use only)
See SMC advice 2216.
Concentrate for solution for infusion 500mg (hospital use only)
See SMC advice 2404.
Solution for infusion 50mg/ml (specialist use only)
See SMC advice 2156.
MHRA advice: Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (October 2019) (www.gov.uk).
MHRA advice: Nivolumab (Opdivo). pembrolizumab (Keytruda): reports of organ transplant rejection (July 2017) (www.gov.uk).
Risk minimisation materials
Concentrate for solution for infusion 10mg/mL (hospital use only)
First choice for indication as per SMC advice 2112.
See SMC advice 1120/16, 1180/16, 1187/16, 1240/17, 1261/17, 1188/16, 2153, 2362, 2385, 2394, 2429, 2458 and 2503.
Solution for injection 40mg/4mL, 100mg/10mL (specialist use only)
See SMC advice 1144/16.
MHRA advice: Nivolumab (Opdivo). pembrolizumab (Keytruda): reports of organ transplant rejection (July 2017) (www.gov.uk).
